Methods and compositions for treating lupus
Patent Information
- Application Number
- JP2023526635
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-01
- Filing Date
- 2021-11-01
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
に上回られているものである。投与は、静脈内で、正確にまたは約の3mg/kg、6mg/kg、10mg/kg、12mg/kg、もしくは24mg/kgを、毎週(1週間に1回)、または隔週(2週間に1回)の頻度であり得る。追加の投薬レジメンは以下に記載されている。
Abstract
Claims
1. A pharmaceutical composition for treating a B cell-driven autoimmune and / or allergic disease, the pharmaceutical composition comprising a non-depleting B cell inhibitor, the disease being characterized by reduced CD32B signaling compared to healthy subjects, and the B cell inhibitor being capable of agonizing CD32B despite reduced CD32B signaling.
2. 2. The pharmaceutical composition of claim 1, wherein the B cell inhibitor is a CD32BxCD79B bispecific antibody capable of immunospecifically binding to an epitope of CD32B and an epitope of CD79B.
3. the CD32B×CD79B bispecific antibody (A) a VL comprising the amino acid sequence of SEQ ID NO: 1 CD32B domain, (B) VH comprising the amino acid sequence of SEQ ID NO:2 CD32B domain, (C) VL comprising the amino acid sequence of SEQ ID NO:3 CD79B Domain, and (D) VH comprising the amino acid sequence of SEQ ID NO: 4 CD79B domain The pharmaceutical composition of claim 2 , comprising:
4. the CD32B×CD79B bispecific antibody (A) a first polypeptide chain comprising the amino acid sequence of SEQ ID NO:5; (B) a second polypeptide chain comprising the amino acid sequence of SEQ ID NO:6, and (C) a third polypeptide chain comprising the amino acid sequence of SEQ ID NO:
7. The pharmaceutical composition of claim 3, wherein the Fc diabody comprises
5. 5. The pharmaceutical composition of claim 4, wherein said Fc diabody is administered at a dose of about 5 mg / kg to about 40 mg / kg, in a 1 dose / 2-8 week dosing regimen, for a total of 2-20 doses.
6. 5. The pharmaceutical composition of claim 4, wherein said Fc diabody is administered at a dose of about 5-20 mg / kg in a dosing regimen of one dose every 2-6 weeks for a total of 5-10 doses.
7. 5. The pharmaceutical composition of claim 4, wherein said Fc diabody is administered at a dose of about 10 mg / kg in a 1 dose / 2-4 week dosing regimen for a total of 6-8 doses.
8. 5. The pharmaceutical composition of claim 4, wherein said Fc diabody is administered at a dose of about 10 mg / kg in a dosing regimen of one dose every four weeks for a total of six doses.
9. The pharmaceutical composition of claim 4, wherein the Fc diabody is administered via intravenous infusion.
10. 10. The pharmaceutical composition of claim 9, wherein the Fc diabody is administered for a period of about 1 to 10 hours, or about 2 to 4 hours, or about 2 hours.
11. The pharmaceutical composition of claim 8, wherein the Fc diabody is administered via intravenous infusion.
12. 12. The pharmaceutical composition of claim 11, wherein the Fc diabody is administered for a period of about 1 to 10 hours, or about 2 to 4 hours, or about 2 hours.
13. The pharmaceutical composition according to any one of claims 1 to 13, wherein the disease is selected from systemic lupus erythematosus (SLE), multiple sclerosis (MS), rheumatoid arthritis (RA), psoriasis, dermatomyositis / polymyositis, Sjogren's syndrome (SS), primary vasculitis (e.g. rheumatic polymyositis / giant cell arteritis / Behcet's disease), graft-versus-host disease (GVHD), myasthenia gravis, pemphigus, neuromyelitis optica, anti-NMDA receptor encephalitis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), Graves' ophthalmopathy, IgG4-related disease (IgG4-RD), idiopathic thrombocytopenic purpura (ITP), inflammatory bowel disease (IBD), and Crohn's disease.
14. The pharmaceutical composition according to any one of claims 1 to 13, wherein the disease is systemic lupus erythematosus.
15. The pharmaceutical composition according to any one of claims 1 to 13, wherein the disease is chronic systemic lupus erythematosus.
